The number of fat cells in WAT of the C/EBPβΔuORF/BL6 mice, as can be calculated from the fat volume (CT analysis) and cell size (histology), does not seem to be altered, indicating that the reduction of fat mass observed in C/EBPβΔuORF/BL6 mice results from less fat storage.
Naïve mice were used as controls.
After intravenous administration of 200 mg/kg cefazolin, the plasma unbound concentration of cefazolin in mice reaches 445 μM, as calculated from the volume of distribution of cefazolin, unbound fraction of drug in plasma and half-life in circulating blood [ 40, 41].
The sensitivity of BLI and PET in relation to the post mortem findings was calculated for mice as well as for lesions.
Moreover, our data indicated that the urea and creatinine clearance measurements in mice should be adjusted to BSA as calculated based on the weight and length of these animals, to ensure that no systematic or random errors occur.
The placebo (control) mice developed 22.33% parasitemia at the end of day 6, where as parasitemia in ACF and CQ treated mice was calculated as 1.04% and 0.35%, respectively, as indicated in Figure 2A.
When compared with wild type (determined as 100% volume), the alveolar bone volume of caspase-7-deficient mice was calculated as 76%.
Considering average weight of humans and mice to be 70 kg and 20 g, respectively, the nasal dose for mice was calculated as per the conversion factor based on body surface area as (3) Mouse dose = human dose × 0.0026 = 2.6 μ g.
For instance, the expected DMI (additive) for Ly49C in KbDb mice was calculated as DMI in Db-single mice + DMI in Kb-single mice.
